Kopran Ltd Q2 FY26 – From Antibiotics to Diagnostics: A Pharmaceutical Comedy of Errors and Expansion
1. At a Glance
Kopran Ltd, the smallcap pharma veteran that once flexed with Atenolol and antibiotics, is now mixing diagnostic reagents into its pill cocktail. At ₹140 a share, this ₹676 crore market cap company sits on a P/E of 38.4—proof that optimism is the most powerful drug on Dalal Street. Quarterly sales have dipped 22%, profit has turned negative, and the OPM has fallen into the “doctor please prescribe margin boosters” zone. The 3-month return? A bitter -15.8%, which makes you wonder if shareholders are more patient than patients.
Still, the company’s merger with Kopran Laboratories promises a new phase—one that includes diagnostics, hospital networks, and possibly fewer sleepless nights over negative EPS. With exports at 43%, domestic sales at 57%, and a fancy new diagnostics ambition, Kopran is the pharma equivalent of a doctor learning AI—ambitious but slightly confused.
2. Introduction
Once upon a pharma time, Kopran Ltd was known for its beta-blockers and antibiotic blends. Today, it’s trying to upgrade its prescription—moving from the chemistry lab to the pathology lab. This pivot from tablets to test kits is bold, but like every medical experiment, it comes with side effects: declining profitability, rising debt, and a P/E ratio that screams “hope is not a strategy.”
If you’ve been holding this stock for five years, congratulations—you’ve experienced the full range of human emotions: optimism, despair, disbelief, and finally, resignation. The stock’s five-year return is basically flatlined (-0.10%), which is ironic for a company that sells life-saving drugs.
But there’s drama too: the merger with Kopran Laboratories aims to give the company a diagnostic twist in a market projected to jump from $14 billion to $25 billion by FY28. Kopran’s management says this will create “synergies.” Translation: they’re hoping hospitals buy both your antibiotics and your blood test kits.
Will this transformation turn Kopran into a small-cap diagnostic dynamo or just another over-prescribed patient in the BSE Healthcare ward? Let’s dig in.
3. Business Model – WTF Do They Even Do?
Kopran runs on two main engines — APIs and Formulations.
The API Vertical, operated through its wholly owned subsidiary Kopran Research Laboratories, makes active pharmaceutical ingredients (APIs) and intermediates. Think of it as the raw chemical soup before it becomes the tablet you pop after regretting street food. They’re one of the global leaders in Atenolol (used for hypertension) and manufacture around 26 commercial products.
Then comes the Formulations Vertical, where chemistry meets commerce. Here, the company produces tablets, capsules, injectables, and syrups — the usual suspects. Interestingly, it does both Penicillin and Non-Penicillin products, which is like selling both tea and coffee and still managing to spill both.
Kopran claims 100% export focus in formulations, reaching 50+ countries, from South Africa to Southeast Asia. However, the export contribution has lately dropped to 43%, showing that global trade winds aren’t always gentle.
Their two factories — one in Mahad for APIs and another in Khopoli for formulations — are decently sized and well certified. Yet, even great facilities can’t save margins if raw material costs rise faster than paracetamol prices during monsoon.
4. Financials Overview
Let’s inject some hard numbers — no sugar-coating.
Metric
Q2 FY26
Q2 FY25
Q1 FY26
YoY %
QoQ %
Revenue (₹ Cr)
117.91
151.56
135.22
-22.2%
-12.8%
EBITDA (₹ Cr)
-5.28
14.73
14.13
-135.9%
-137.4%
PAT (₹ Cr)
-9.92
7.38
7.45
-234%
-233%
EPS (₹)
-2.06
1.53
1.54
-234%
-233%
From profits to losses, Kopran’s P&L has done a full somersault. YoY revenue dropped 22%, but the real horror is the EBITDA going negative. The operating profit margin has shrunk from 9.7% to -4.5%. It’s as if the balance sheet caught a bad infection.
The annualized EPS (if we ignore this quarter’s infection) would’ve been ~₹8 earlier, but now it’s negative. Pharma investors call that “clinical depression.”
5. Valuation Discussion – Fair Value Range (Educational Only)
Method 1: P/E Method Industry median P/E: 31.7 Kopran’s EPS (TTM): ₹3.65
Fair Value Range = ₹3.65 × (25 to 35) = ₹91 – ₹128
Method 2: EV/EBITDA EV = ₹795 Cr EBITDA (TTM) = ₹46 Cr EV/EBITDA = 17.3× (premium to peers) If normalized multiple = 12× → EV Fair Value = 12 × 46 = ₹552 Cr → Equity Value ≈ ₹550–₹600 Cr → ₹115 – ₹125 per share
